New updates have been launched by the Advisory Council on the Misuse of Drugs in relation to reducing the barriers to research using compounds described by the third generation synthetic cannabinoid receptor agonists generic definition.
You can read the letter from the chair of the advisory council here:
In December 2016 the Misuse of Drugs Act and Regulations were amended to include a generic definition for third generation synthetic cannabinoids. This amendment, however, inadvertently also controlled a large number of compounds that had no psychoactivity, and thus are not SCRA compounds.
In 2017 the then Policing Minister wrote to the ACMD asking the Council to review the barriers to research caused by the inadvertent control of non-SCRA compounds. The ACMD made some initial advice in late 2017 that included potential short- and long-term solutions. In January 2019 the short-term advice was accepted but the long-term suggestions were all deemed unfeasible.
You can also read their full report on this issue here:
After reviewing the situation further with a call for evidence, consideration of international approaches, and additional representations from the research community this advice was formulated to make other long-term options available.
We will keep you abreast of any updates that may arise in the future on our DnD blog and through our social media pages. If you don’t already follow us to keep up to date with the latest news, recovery strategies and techniques, now is the perfect time to start. You can find the links to our social media pages here!